HalioDx has its GCP laboratory in Marseille, France and two CLIA laboratories : Marseille France and Richmond, Virginia, USA.
HalioDx has developed pharma services for exploratory biomarker testing, Clinical trial assay and CDx developments for all phases of a clinical trial. HalioDx offers testing compliant with GCP (Good Clinical Practice) or GCLP (Good Clinical and Laboratory Practice) requirements for patient testing.
HalioDx can organize shipment of patient samples from recruiting centers if needed.
HalioDx offers single IHC testing on Frozen Samples and FFPE samples.
HalioDx does not do Fluorescence IHC testing but has developed a multiplex IHC technology, Brightplex®, which can combine up-to 7 biomarkers on 1 FFPE slide.
HalioDx can use protocol to transfer it to its lab. However, some development might be required.
HalioDx has developed pharma services for exploratory biomarker testing, Clinical trial assay and CDx developments for all phases of a clinical trial. Samples and testing traceability are compliant.
HalioDx has an expert team for bioinformatics and biostatistics.
HalioDx offers testing for RNA expression and DNA sequencing.
RNA and DNA can be extracted from FFPE tissues or frozen tissues.
HalioDx is doing testing mainly on human tissues. Only Molecular testing can be performed on mice and/or other animals.
IHC testing can be performed only on humanized Mice/ and or other animals.
AACR2020 Abstract # 5970
AACR2020 Poster # 870
Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.
In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.
Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.
High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.
Unveilling tumor-associated macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay.
Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Tumor Immunology and Tumor Evolution: Intertwined Histories
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma
A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma
Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
HalioDx Biopharma Services
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
Evolution of Metastases in Space and Time under Immune Selection.
T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)
A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study
A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections
LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.